Qualigen Therapeutics to Present at BIO International Convention
14 juin 2022 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
13 avr. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
31 mars 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
16 févr. 2022 09h40 HE
|
Hillstream BioPharma Inc.
-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell...
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
06 janv. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
16 sept. 2021 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 sept. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
09 sept. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor
20 août 2021 09h00 HE
|
Vitality Biopharma, Inc
CLEVELAND, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...